TITLE

FDA approves Eli Lilly's Zyprexa in bipolar I disorder

PUB. DATE
September 2003
SOURCE
PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p12
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the approval of the U.S. Food and Drug Administration to Eli Lilly & Co.'s Zyprexa antidepressant as a combination therapy in bipolar I disorder. Basis for the regulatory decision; Safety and efficacy of Zyprexa; Response of patients taking Zyprexa.
ACCESSION #
13861323

 

Related Articles

  • FDA approves Lilly bipolar medication. Adams, Brent // Indianapolis Business Journal;1/5/2004, Vol. 24 Issue 44, p25A 

    Reports that the U.S. Food and Drug Administration has approved Symbyax, a drug developed by Eli Lilly and Co. to treat depressive episodes associated with bipolar disorders.

  • Eli Lilly's Symbyax seen to reduce symptoms of suicidal thinking in patients with bipolar depression.  // PharmaWatch: CNS;June 2004, Vol. 3 Issue 6, p25 

    Presents data showing the capability of Eli Lilly & Co.'s Symbyax to reduce symptoms of suicidal thinking in patients with bipolar depression. Likelihood of patients having an early onset of bipolar disorder to respond to Symbyax; Approval of the U.S. Food and Drug Administration to Symbyax as...

  • Eli Lilly: firmer footing for Zyprexa.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p9 

    Reports on the approval of the U.S. Food and Drug Administration to Eli Lilly ↦ Co.'s Zyprexa for combination treatment of mania in bipolar disorder. Number of people afflicted with manic-depressive disorder; Sales of Zyprexa; Stance of the company in the bipolar market.

  • Antipsychotic cleared for bipolar disorder.  // Drug Topics;1/26/2004, Vol. 148 Issue 2, p8 

    Reports on the approval of olanzapine from Eli Lilly and Co. for the maintenance treatment of bipolar disorder by the U.S. Food and Drug Administration.

  • FDA APPROVES LILLY'S ZYPREXA FOR TWO ADOLESCENT INDICATIONS.  // Psychiatry (1550-5952);Dec2009, Vol. 6 Issue 12, p10 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the drug Zyprexa from Eli Lilly & Co. for the treatment of schizophrenia and bipolar I disorder in adolescents aged 13 to 17 years old. It notes that the tablet form of Zyprexa has been labeled to have side effects...

  • Eli Lilly: Cymbalta finally approved.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p15 

    Reports that Eli Lilly and Co.'s antidepressant drug Cymbalta has gained United States Food and Drug Administration approval for the treatment of major depressive disorder. Common side effects; Drug's dual action; Ability of the drug to treat pain in depression. Forecast sales in 2005.

  • Eli Lilly: Cymbalta finally approved.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p20 

    Reports on the United States Food and Drug Administration's (FDA) approval of Eli Lilly's Cymbalta for the treatment of major depressive disorder. Basis of FDA approval of Cymbalta; Significance of the FDA approval of the drug on Eli Lilly; Overview on the competition in the antidepressant market.

  • Crymbalta could be next treatment for fibromyalgia. Wall, J.K. // Indianapolis Business Journal;3/10/2008, Vol. 29 Issue 1, HEALTH CARE HEROES p10 

    The article reports that drug company Eli Lilly and Co. is presenting its antidepressant drug called Cymbalta to the United States Food and Drug Administration (FDA) for approval to treat fibromyalgia. Eli Lilly has asked the FDA in the third quarter of 2007 to approve the drug and...

  • Zyprexa era comes to an end for Lilly as generic versions begin.  // Indianapolis Business Journal;10/31/2011, Vol. 32 Issue 35, p13A 

    The article reports on the approval of Eli Lilly & Co.'s antipsychotic medication, Zyprexa, by the U.S. Food and Drug Administration (FDA) in 2011.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics